Axon Enterprise, Inc (NASDAQ:AXON) Shares Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC lifted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 118.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 122,250 shares of the biotechnology company’s stock after purchasing an additional 66,320 shares during the period. TimesSquare Capital Management LLC’s holdings in Axon Enterprise were worth $64,297,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Pinion Investment Advisors LLC increased its position in shares of Axon Enterprise by 3.0% during the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 19 shares in the last quarter. Kentucky Retirement Systems increased its position in shares of Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company’s stock worth $2,605,000 after purchasing an additional 19 shares in the last quarter. WCM Investment Management LLC increased its position in Axon Enterprise by 0.8% in the 1st quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company’s stock valued at $1,306,000 after acquiring an additional 19 shares during the period. HBK Sorce Advisory LLC increased its position in Axon Enterprise by 4.6% in the 1st quarter. HBK Sorce Advisory LLC now owns 451 shares of the biotechnology company’s stock valued at $237,000 after acquiring an additional 20 shares during the period. Finally, Prudent Man Advisors LLC increased its position in Axon Enterprise by 1.6% in the 1st quarter. Prudent Man Advisors LLC now owns 1,298 shares of the biotechnology company’s stock valued at $683,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th. Bank of America boosted their price target on Axon Enterprise from $750.00 to $895.00 and gave the company a “buy” rating in a research report on Wednesday, June 4th. Wolfe Research assumed coverage on Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating on the stock. Needham & Company LLC boosted their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Finally, Barclays boosted their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $699.55.

Axon Enterprise Price Performance

Shares of AXON opened at $729.62 on Monday. Axon Enterprise, Inc has a twelve month low of $279.02 and a twelve month high of $830.21. The stock’s 50 day moving average is $752.67 and its two-hundred day moving average is $641.14. The firm has a market capitalization of $56.80 billion, a PE ratio of 176.24, a P/E/G ratio of 83.99 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 EPS. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 75 shares of the business’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the sale, the chief accounting officer owned 15,240 shares of the company’s stock, valued at $11,762,384.40. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Garnreiter sold 5,913 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the sale, the director directly owned 17,740 shares in the company, valued at $13,482,400. This trade represents a 25.00% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,642 shares of company stock worth $30,500,428. Corporate insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.